Adaptive Biotechnologies Corp ADPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $18.73
- Day Range
- $17.10–19.53
- 52-Week Range
- $9.90–20.76
- Bid/Ask
- $17.69 / $17.80
- Shares Outstanding
- 160.04M
- Market Cap
- $2.82B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 4,260.69
- Price/Sales
- 9.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 624
- Website
- https://www.adaptivebiotech.com
Valuation
|
Metric
|
ADPT
|
|---|---|
Price/Earnings (Normalized) | 4,260.69 |
Price/Book Value | 13.83 |
Price/Sales | 9.72 |
Price/Cash Flow | 137.52 |
Price/Earnings
ADPT
Financial Strength
|
Metric
|
ADPT
|
|---|---|
Quick Ratio | 3.06 |
Current Ratio | 3.35 |
Interest Coverage | −3.97 |
Quick Ratio
ADPT
Profitability
|
Metric
|
ADPT
|
|---|---|
Return on Assets (Normalized) | 0.39% |
Return on Equity (Normalized) | 0.98% |
Return on Invested Capital (Normalized) | 1.70% |
Return on Assets
ADPT
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Qbxndkcfq | Fnd | $174B | |||
| Danaher Corp
DHR
| Llfbkpdmk | Pbmb | $127B | |||
| IDEXX Laboratories Inc
IDXX
| Xsnrmnyw | Cncdb | $44B | |||
| Agilent Technologies Inc
A
| Yqzjbtwbq | Nbc | $37B | |||
| Waters Corp
WAT
| Jrtdlwpv | Pjhl | $35B | |||
| IQVIA Holdings Inc
IQV
| Ptqvxkpt | Xtwjhx | $30B | |||
| Illumina Inc
ILMN
| Zyfmxmcg | Jlrzfz | $24B | |||
| Mettler-Toledo International Inc
MTD
| Jdfnllkkp | Gzlctdp | $23B | |||
| Quest Diagnostics Inc
DGX
| Gfcqpwc | Rcsqcv | $22B | |||
| Labcorp Holdings Inc
LH
| Cvwwnztqcs | Zjrhqlj | $22B |
United States